Advancing vaccine development through green biotechnology

The diseases hepatitis B (HBV) and C (HCV) remain a significant health threat worldwide, causing approximately 1.3 million deaths each year.

Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for two more trials

Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored

May 14, 2024

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity – Biotech Investments

Kinarus Therapeutics Holding AG / Key word(s): Financing 27-Jun-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

June 27, 2023

Replay wins IND clearance for PRAME T cell cancer therapy – Pharmaceutical Technology

The Phase I/II clinical trial will investigate the T cell therapy in patients with haematological malignancies. Credit: Yomal2233 via Shutterstock. Genome writing company Replay Bio

May 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.